Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the amount of two incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are normally produced naturally by the body in response to food intake. Their function is to help control blood sugar (glucose) levels. It is used to treat type 2 or non-insulin dependent diabetes (NIDDM) in combination with a sulphonyl urea, metformin or a glitazone.
Vildagliptin falls under the Antidiabetic therapeutic category.
IUPAC Name :
Molecular weight – 303.40 g/mol
Molecular Formula: C17H25N3O2
Molecular Structure -
Mechanism Of Action:
Vildagliptin, previously identified as is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas.Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4). This in turn inhibits the inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta cells. Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP and the degradation of GLP-1.